Clinical And Dosimetric Analyses Of Acute Xerostomia For Hypopharynx And Larynx Carcinoma Treated By Rotational Imrt

Boning Cai,Chuanbin Xie,Wei Yu,Shouping Xu,Xiaoshen Wang,Jinyuan Wang,Lin Ma
2016-01-01
Abstract:Objective: To evaluate acute xerostomia in the concurrent chemoradiotherapy of locally advanced squamous cell carcinoma of the hypopharynx and larynx (LA-SCCH/L) realized with Helical tomotherapy (HT) and RapidArc (RA). Methods: Between August 2008 and December 2014, 80 patients with LA-SCCH/L were treated by HT or RA, and combined with concurrent cisplatin-based chemotherapy. The prescription dose was 69 similar to 70 Gy to pGTVnx and pGTVnd, 60 Gy to PTV1 and 54 Gy to PTV2, in 30 similar to 33 fractions; respectively. The endpoint was >= grade 2 (G2) acute xerostomia. The clinical and dosimetric factors were analyzed. Results: Patients treated with HT had lower incidence of G2 xerostomia than RA (P = 0.025). Through the limit of parotid Dmean, other parotid parameters were not correlated to the xerostomia. Multivariate analyses showed that ICT was independently associated G2 xerostomia (P = 0.003). Both of HT and RA had good protection in parotid gland. However, RA had lower parotid Dmean than HT. Conclusions: In the treatment of LA-SCCH/L, HT and RA are effective in protecting the parotid, without significant difference in acute xerostomia. ICT is the predictor of xerostomia.
What problem does this paper attempt to address?